International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026
Culture-proven osteoarticular mycoses: An eight-year single-center descriptive study of fungal distribution and antifungal susceptibility trends.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gibert Charles, Dauwalder Olivier, Tirard-Collet Pauline, Dupont Damien, Dupieux Céline, Wallon Martine, Conrad Anne, Valour Florent, Menotti Jean, Ferry Tristan, Lyon BJI Study Group
Аннотация
OBJECTIVES: To describe the mycological profile of culture-proven osteoarticular mycoses (OAM) at a 5400-bed university hospital (2017-2024) according to clinical syndromes, and assess antifungal resistance trends.
METHODS: Adults with deep osteoarticular specimens (bone, joint fluid, prosthetic material) positive by culture were retrospectively included. Isolations within ±15 days were grouped as a sample batch (SB). Patients were classified into four categories: ``Traumatic injury infection,'' ``Infection of prostheses and other materials,'' ``Craniofacial infection'' and ``Other infections''. Antifungal susceptibility testing (AST) was performed using gradient strips.
RESULTS: Three hundred fifty-seven patients yielded 1993 analyzed specimens and 380 SB. Yeasts predominated outside ``Traumatic injury infection'' (range from 88.3 to 96.2%), mainly Candida albicans and Candida parapsilosis, whereas ``Traumatic injury infection'' was mold-dominant (64.0%), chiefly Aspergillus and Fusarium. AST was available for 306/357 (85.7%) Candida isolates; fluconazole resistance was found in 12/36 (33.3%) Candida glabrata, 5/67 (7.5%) C. parapsilosis, and 2/21 (9.5%) Candida tropicalis. No Aspergillus resistance was detected. Recurrence occurred in 18/357 (5.0%) patients; three developed azole resistance.
CONCLUSIONS: OAM shows syndrome-specific fungal profiles, supporting syndrome-adapted diagnostic and therapeutic approaches. Although susceptibility profiles were largely stable, resistant and evolving phenotypes justify repeat culture and susceptibility testing during follow-up of these chronic infections.
METHODS: Adults with deep osteoarticular specimens (bone, joint fluid, prosthetic material) positive by culture were retrospectively included. Isolations within ±15 days were grouped as a sample batch (SB). Patients were classified into four categories: ``Traumatic injury infection,'' ``Infection of prostheses and other materials,'' ``Craniofacial infection'' and ``Other infections''. Antifungal susceptibility testing (AST) was performed using gradient strips.
RESULTS: Three hundred fifty-seven patients yielded 1993 analyzed specimens and 380 SB. Yeasts predominated outside ``Traumatic injury infection'' (range from 88.3 to 96.2%), mainly Candida albicans and Candida parapsilosis, whereas ``Traumatic injury infection'' was mold-dominant (64.0%), chiefly Aspergillus and Fusarium. AST was available for 306/357 (85.7%) Candida isolates; fluconazole resistance was found in 12/36 (33.3%) Candida glabrata, 5/67 (7.5%) C. parapsilosis, and 2/21 (9.5%) Candida tropicalis. No Aspergillus resistance was detected. Recurrence occurred in 18/357 (5.0%) patients; three developed azole resistance.
CONCLUSIONS: OAM shows syndrome-specific fungal profiles, supporting syndrome-adapted diagnostic and therapeutic approaches. Although susceptibility profiles were largely stable, resistant and evolving phenotypes justify repeat culture and susceptibility testing during follow-up of these chronic infections.